See more : CITIC Capital Acquisition Corp. (CCAC-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Redx Pharma Plc (REDX.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Redx Pharma Plc, a leading company in the Biotechnology industry within the Healthcare sector.
- DV8 Public Company Limited (DV8.BK) Income Statement Analysis – Financial Results
- Chiyoda Co., Ltd. (8185.T) Income Statement Analysis – Financial Results
- Seiko PMC Corporation (4963.T) Income Statement Analysis – Financial Results
- Alpha Metallurgical Resources, Inc. (AMR) Income Statement Analysis – Financial Results
- Nakano Corporation (1827.T) Income Statement Analysis – Financial Results
Redx Pharma Plc (REDX.L)
About Redx Pharma Plc
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.20M | 18.69M | 10.04M | 5.69M | 3.13M | 129.00K | 30.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 960.00K | 0.00 | 0.00 | 0.00 | 350.00K | 0.00 | 0.00 | 262.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.24M | 18.69M | 10.04M | 5.69M | 2.78M | 129.00K | 30.47M | -262.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 77.15% | 100.00% | 100.00% | 100.00% | 88.82% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 29.12M | 28.56M | 24.45M | 9.94M | 6.17M | 5.73M | 8.17M | 8.07M | 5.10M | 2.90M | 3.75M | 2.04M |
| General & Administrative | 8.07M | 10.23M | 6.46M | 50.00K | 50.00K | 177.00K | 2.93M | 42.00K | 27.00K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.07M | 10.23M | 6.46M | 50.00K | 50.00K | 177.00K | 2.93M | 42.00K | 27.00K | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | -1.54M | -1.12M | 3.97M | 3.76M | 3.37M | 5.94M | 6.28M | 4.31M | 4.01M | 3.33M | 2.31M |
| Operating Expenses | 35.18M | 37.25M | 29.78M | 13.96M | 9.97M | 9.33M | 17.42M | 14.39M | 9.43M | 4.01M | 3.33M | 2.31M |
| Cost & Expenses | 35.18M | 37.25M | 29.78M | 13.96M | 10.32M | 9.33M | 17.42M | 14.39M | 9.43M | 4.01M | 3.33M | 2.31M |
| Interest Income | 1.22M | 187.00K | 13.00K | 7.00K | 12.00K | 24.00K | 38.00K | 67.00K | 59.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.80M | 1.73M | 1.71M | 974.00K | 102.00K | 1.00K | 368.00K | 526.00K | 348.00K | 240.00K | 240.00K | 60.00K |
| Depreciation & Amortization | 960.00K | 1.07M | 646.00K | 672.00K | 103.00K | 164.00K | 327.00K | 262.00K | 139.00K | 252.00K | 239.00K | 58.00K |
| EBITDA | -32.02M | -19.22M | -19.10M | -8.47M | -7.18M | -9.01M | 13.42M | -14.06M | -9.23M | -3.77M | -3.10M | -2.31M |
| EBITDA Ratio | -695.93% | -81.29% | -190.32% | -133.72% | -226.45% | -6,987.60% | 44.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -33.82M | -16.27M | -19.75M | -8.27M | -7.19M | -10.17M | 1.98M | -14.95M | -9.43M | -4.01M | -3.33M | -2.31M |
| Operating Income Ratio | -804.85% | -87.03% | -196.76% | -145.54% | -229.73% | -7,882.95% | 6.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.03M | 1.24M | -2.40M | -1.32M | 858.00K | 23.00K | -10.45M | -459.00K | 606.00K | -249.00K | -253.00K | -114.00K |
| Income Before Tax | -32.79M | -17.80M | -21.44M | -9.17M | -6.34M | -10.15M | 1.65M | -15.41M | -8.83M | -4.26M | -3.58M | -2.43M |
| Income Before Tax Ratio | -780.30% | -95.26% | -213.68% | -161.27% | -202.33% | -7,865.12% | 5.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 368.00K | 201.00K | 133.00K | 45.00K | -2.02M | -1.30M | 118.00K | 114.00K | -650.00K | -910.00K | -389.00K | -323.00K |
| Net Income | -33.16M | -18.01M | -21.58M | -9.21M | -4.32M | -8.85M | 1.53M | -15.52M | -8.18M | -3.35M | -3.19M | -2.10M |
| Net Income Ratio | -789.05% | -96.33% | -215.01% | -162.06% | -137.91% | -6,856.59% | 5.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.10 | -0.06 | -0.08 | -0.05 | -0.03 | -0.07 | 0.01 | -0.20 | -0.14 | -0.05 | -0.05 | -0.03 |
| EPS Diluted | -0.10 | -0.06 | -0.08 | -0.05 | -0.03 | -0.07 | 0.01 | -0.20 | -0.14 | -0.05 | -0.05 | -0.03 |
| Weighted Avg Shares Out | 334.91M | 294.18M | 256.43M | 170.14M | 126.51M | 126.51M | 113.08M | 78.40M | 58.05M | 65.01M | 65.01M | 65.01M |
| Weighted Avg Shares Out (Dil) | 334.91M | 294.18M | 256.43M | 170.14M | 126.51M | 126.51M | 113.10M | 78.40M | 58.05M | 65.01M | 65.01M | 65.01M |
Source: https://incomestatements.info
Category: Stock Reports